All In Biotech

NDA 203094 · Gilead Sciences INC

Tybost

Cobicistat · Oral · Cytochrome P450 3A Inhibitor

OrphanDiscontinued

Last checked: Nov 20, 2026Latest source record: Jun 20, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2014

Sep 24, 2014

Approved uses

8

Original approval plus efficacy supplements

Registered trials

155

48 Phase 3, 6 recruiting

FAERS reports

621

582 serious, 64 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 10, 2026.

TYBOST is a CYP3A inhibitor indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection in adults and in pediatric patients weighing at least 14 kg. ( 1.1 ) Limitations of Use : TYBOST is not interchangeable with ritonavir to increase systemic exposure of darunavir 600 mg twice daily, fosamprenavir, saquinavir, or tipranavir due to lack of exposure data. The use of TYBOST is not recommended with darunavir 600 mg twice daily, fosamprenavir, saquinavir, or tipranavir. ( 1.2 , 5.4 ) Complex or unknown mechanisms of drug interactions preclude extrapolation of ritonavir drug interactions to certain TYBOST interactions. TYBOST and ritonavir when administered with either atazanavir or darunavir may result in different drug interactions when used with concomitant medications. ( 1.2 , 5.3 , 7 , 12.3 ) 1.1 Indications Adult Patients: TYBOST is a CYP3A inhibitor indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection in adults [see Dosage and Administration (2.1) ]. Pediatric Patients: TYBOST is a CYP3A inhibitor indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection in pediatric patients weighing at least 14 kg [see Dosage and Administration (2.2) , and Drug Interactions (7.3) ]. 1.2 Limitations of Use TYBOST is not interchangeable with ritonavir to increase systemic exposure of darunavir 600 mg twice daily, fosamprenavir, saquinavir, or tipranavir due to lack of exposure data. The use of TYBOST is not recommended with...

Mechanism: Cobicistat is a mechanism-based inhibitor of cytochrome P450 3A (CYP3A). Inhibition of CYP3A-mediated metabolism by cobicistat increases the systemic exposure of CYP3A substrates atazanavir and darunavir.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 20, 2025 Supplement 17 · Efficacy OrphanLabelLetter
  • Jun 20, 2025 Supplement 18 · Efficacy OrphanLabelLetter
  • Oct 3, 2019 Supplement 14 · Efficacy · priority review OrphanLabelLetter
  • Aug 22, 2019 Supplement 13 · Efficacy · priority review OrphanLetterLabelPediatric CDTL Review
  • Oct 30, 2018 Supplement 12 · Efficacy · priority review LabelLetter
  • Nov 25, 2015 Supplement 3 · Efficacy LabelLetter
  • Sep 24, 2014 Original approval · Type 5 - New Formulation or New Manufacturer LetterLabelReview
  • Sep 24, 2014 Original approval · Efficacy
2 products under this application
  • TYBOST · COBICISTAT 150MG · TABLET, ORAL · Discontinued · TE AB
  • TYBOST · COBICISTAT 90MG · TABLET, ORAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Cobicistat" as an intervention, any sponsor and status, largest first.

All 155 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug interaction181
  • cushing^s syndrome60
  • foetal exposure during pregnancy48
  • immune reconstitution inflammatory syndrome38
  • serotonin syndrome36
  • adrenal insufficiency32
  • off label use29
  • anxiety26
  • drug ineffective25
  • pain25
  • virologic failure24
  • emotional distress22

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20101
20122
20135
201413
201511
201637
201733
201844
201983
202082
202141
202280
202361
202460
202550
202618

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Tybost (Cobicistat)

2024 spending

$270K

Beneficiaries

144

750 claims

Per beneficiary

$1,873

$9.80 per unit

View as table
YearSpending
2020$233,323
2021$241,059
2022$248,359
2023$266,480
2024$269,682

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 156 on PubMed

Sponsor: Gilead Sciences

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.